IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement-biotech.vision

IPA’s Subsidiary BioStrand and BriaCell Announce Artificial Intelligence Collaboration and License Agreement

IPA, a leading biotherapeutics research and technology company, announced that BioStrand BV for IPA’s AI in silico discovery has entered into a research collaboration and licensing agreement with BriaCell Therapeutics Corp. a clinical-stage biotechnology company specializing in targeted cancer therapies.

This collaboration will leverage BioStrand’s LENSai ™ software, based on IPA’s proprietary HYFT ™ Universal Fingerprint ™ technologies, and will focus on in silico antibody discovery to create clinically relevant molecules for development. Under the terms of the Agreement, BioStrand and BriaCell will collaborate on the development, discovery, and development of anti-cancer antibodies. Upon discovery of a successful antibody, BioStrand will receive an advance payment of $500,000 and will be eligible to receive development related to future development, including the submission of Investigational New Drugs clinical fees, and commercial fees on sales of the products. Other expressions were not released.

We are very excited to begin this program with BriaCell and apply our technology to the development of biologics that may have a huge clinical impact. Shortening timelines, while also integrating as much information as possible upstream to improve the efficiency of the process, is extremely important in the development of highly targeted therapies. It is a step towards realizing our long-term vision of significantly advancing precision medicine.”

Dr. Ingrid Brands, General Manager and co-founder of BioStrand

“We believe that BioStrand’s revolutionary AI-powered technology, combined with a cutting-edge protein engineering platform, will enable us to develop and discover powerful cancer therapies,” said Miguel A. Lopez-Lago, Ph.D., Chief Scientific Officer of BriaCell. “This approach complements BriaCell’s current immunotherapy pipeline to develop anti-cancer therapy.”

About BriaCell Therapeutics Corp.

BriaCell is an immuno-oncology-focused biotechnology company that develops targeted and effective cancer treatment strategies.

ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd. has several subsidiaries in North America and Europe including organizations such as Talem Therapeutics LLC, Biostrand BV, ImmunoPrecise Antibodies Ltd., and ImmunoPrecise Antibodies BV. The IPA Family is a biotherapeutic research and technology group that expands systems biology and multi-omics model, and complex artificial intelligence systems to support its technology in bioplatform-based antibody discovery. Services include highly specialized, full-scale therapeutic biologics discovery, development, and out-licensing to support commercial partners in their quest to discover and develop new biologics against the most challenging targets.

Leave a Reply

Your email address will not be published. Required fields are marked *